Child cancer groups call for concerted action
- Details
- Category: Research
Experimental study points to systemic sclerosis treatment
- Details
- Category: Research
Systemic sclerosis, also called scleroderma, is a chronic, life-threatening condition that scars the skin, lungs, heart and other organs.
Protein build-up may shape cancer drug response
- Details
- Category: Research
Researchers found that PROTAC (Proteolysis Targeting Chimeras) drugs were more effective at removing proteins that build up because they are not broken down properly than proteins that cancer cells continually produce in large amounts.
Hidden immune cells in the lung could lead to better flu vaccines
- Details
- Category: Research
Vaccination remains the most effective way to prevent flu infection, but current vaccines do not always stop the virus from taking hold in the respiratory tract.
Novel drug shows promise in an early phase trial in heart failure
- Details
- Category: Research
Despite several guideline-directed medical therapies for heart failure, many patients continue to experience considerable disease burden.
Cholesterol-lowering medication reduces heart attack and stroke risk in older people by 30%
- Details
- Category: Research
Statins are commonly prescribed to manage high cholesterol in people up to 75 years, and are known to reduce the risk of heart attack and stroke.
Scientists decode gene circuits of human immunity, fueling new era of disease research
- Details
- Category: Research
Published in the journal Cell, the study represents a landmark achievement in immunology and genomics.
More Pharma News ...
- Rethinking oral cancer treatment: A review of next-generation drug delivery systems
- A ray of hope in the fight against cancer
- Novel combination therapy improves treatment outcomes in preclinical lung cancer models
- First-in-class therapy targets "undruggable" protein in hard-to-treat blood cancers
- AI designs a novel E. coli killer
- GLP-1 drug linked to heart benefits for high-risk patients
- FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber